DSP 0038
Alternative Names: DSP-0038Latest Information Update: 20 Jul 2023
At a glance
- Originator Exscientia; Sunovion Pharmaceuticals
- Developer Exscientia
- Class Antipsychotics; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psychotic disorders
Most Recent Events
- 14 Feb 2023 Phase I development is ongoing for Psychotic disorders in USA (PO) (Sunovion Pharmaceuticals pipeline, February 2023)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 12 May 2021 Phase-I clinical trials in Psychotic disorders in USA (PO) before May 2021 (Sumitomo Dainippon Pharma's pipeline, May 2021)